Enliven Therapeutics (NASDAQ:ELVN) Given New $73.00 Price Target at HC Wainwright

Enliven Therapeutics (NASDAQ:ELVN) had its price objective hoisted by HC Wainwright from $65.00 to $73.00 in a report published on Monday,Benzinga reports. They currently have a buy rating on the stock.

Several other equities analysts have also issued reports on the company. Morgan Stanley initiated coverage on Enliven Therapeutics in a report on Friday, October 2nd. They issued an “overweight” rating and a $70.00 target price for the company. JonesTrading lifted their price target on Enliven Therapeutics from $45.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Stifel Nicolaus lifted their price target on Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. JPMorgan Chase & Co. assumed coverage on Enliven Therapeutics in a research report on Thursday, October 1st. They issued an “overweight” rating and a $75.00 price objective on the stock. Finally, Wall Street Zen cut Enliven Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Ten equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $75.44.

Enliven Therapeutics Stock Up 3.7%

Shares of ELVN stock opened at $38.70 on Monday. Enliven Therapeutics has a 52-week low of $14.78 and a 52-week high of $62.32. The company has a 50-day simple moving average of $51.60 and a two-hundred day simple moving average of $47.95.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Equities research analysts predict that Enliven Therapeutics will post -1.81 earnings per share for the current year.

Insider Activity at Enliven Therapeutics

In related news, CFO Benjamin Hohl sold 6,018 shares of the firm’s stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $50.35, for a total transaction of $303,006.30. Following the completion of the sale, the chief financial officer owned 38,000 shares in the company, valued at approximately $1,913,300. This trade represents a 13.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director J. Scott Garland sold 13,000 shares of the firm’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $46.67, for a total transaction of $606,710.00. Following the sale, the director owned 13,000 shares of the company’s stock, valued at $606,710. This trade represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 183,831 shares of company stock worth $10,823,298. 3.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in Enliven Therapeutics in the 2nd quarter valued at about $221,255,000. First Light Asset Management LLC boosted its position in Enliven Therapeutics by 574.1% during the second quarter. First Light Asset Management LLC now owns 1,360,750 shares of the company’s stock worth $69,058,000 after purchasing an additional 1,158,883 shares during the period. Assenagon Asset Management S.A. increased its stake in shares of Enliven Therapeutics by 276.4% in the third quarter. Assenagon Asset Management S.A. now owns 1,153,973 shares of the company’s stock worth $52,898,000 after purchasing an additional 847,399 shares in the last quarter. Rock Springs Capital Management LP increased its stake in shares of Enliven Therapeutics by 3.5% in the first quarter. Rock Springs Capital Management LP now owns 826,500 shares of the company’s stock worth $32,399,000 after purchasing an additional 28,095 shares in the last quarter. Finally, Siren L.L.C. purchased a new position in shares of Enliven Therapeutics in the first quarter worth about $29,252,000. 95.08% of the stock is owned by institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc (NASDAQ: ELVN) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company seeks to develop therapies designed to address significant unmet needs in oncology, with an emphasis on targeted treatments that may offer improved efficacy, safety, or durability.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for patients with chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for the treatment of HER2-driven cancers.